NCT02527317View on ClinicalTrials.gov

Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Breast Cancer
Interventions
DRUG

Lipegfilgrastim

Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).

Trial Locations (1)

DUBLIN 9

Beaumont Hospital, Dublin

All Listed Sponsors
lead

Beaumont Hospital

OTHER

NCT02527317 - Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer | Biotech Hunter | Biotech Hunter